Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2979 | Placebo oral capsule Wiki | 0.58 |
| drug2981 | Placebo oral tablet Wiki | 0.18 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A randomized, double-blind, placebo-controlled Phase 2 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
Description: 7-point ordinal scale, a higher score is worse than a low score. Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extra-corporeal membrane oxygenation; Death.
Measure: Health status of the patient on the 7-point ordinal scale (World Health Organization) compared to placebo Time: On Day 14Description: This will be assessed through monitoring and probing
Measure: The safety of LAU-7b therapy will be assessed through the monitoring of treatment emergent adverse events, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Rate of COVID-19 disease-related aggravation, depicted by a change from baseline in the ordinal scale score of at least one category, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Rate of COVID-19 disease-related transfer to intensive care unit, depicted by a change from baseline in the ordinal scale score to categories 5 or 6, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Rate of COVID-19 disease-related transfer to mechanical ventilation, depicted by a change from baseline in the ordinal scale score to category 6, compared to placebo Time: From baseline to Day 29Description: This will be assessed through Days 14 and 29 health status scoring using the 7-point ordinal scale
Measure: Rate of COVID-19 disease-related death, depicted by a change from baseline in the ordinal scale score to category 7 Time: On Days 14 and 29Description: 7-point ordinal scale, a higher score is worse than a low score. Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extra-corporeal membrane oxygenation; Death.
Measure: Health status of the patient on the 7-point ordinal scale (World Health Organization), compared to placebo Time: On Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Mean change from baseline of the ordinal scale patient health status as a function of assessment time, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Time to an improvement of one category on the ordinal scale patient health status, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Time to recovery, defined here as the time to reach categories 2 or 1 on the ordinal scale patient health status (first occurrence if more than once), compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Time to mechanical ventilation, defined here as time to reach category 6 on the ordinal scale patient health status, compared to placebo Time: From baseline to Day 29Description: This will be assessed through daily health status scoring using the 7-point ordinal scale
Measure: Time to death, defined here as a tim to reach category 7 on the ordinal scale patient health status, censored to Day 29 if it happens later than Day 29, compared to placebo Time: From baseline to Day 29Description: Monitoring of the hospitalization
Measure: Duration of hospitalization (days) within the study period Days 1-29, compared to placebo Time: From baseline to Day 29Description: This will be assessed through serial oropharyngeal swabs for SARS-CoV-2 viral detection
Measure: Time to attain an undetectable viral load through oropharyngeal swabs done at specified times, compared to placebo Time: On Days 1, 5, 8, 12 and 14Description: This will be assessed through questionnaire filling, in person or remotely
Measure: The change from baseline in the score obtained on the EQ-5D-5L quality-of-life survey Time: On Days 1, 14, 29 and 60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports